Biognosys appoints new Chairman
Vink is very experienced. He has been working for more than 25 years in the life science sector. Before joining Biognosys he was COO at Cubist Pharmaceuticals Inc., a Merck & Co subsidiary since 2015. There he was responsible for the worldwide commercial and technical operations and the global alliance management. Prior that Vink was Head of the Global Hospital Business and executive team member at Mylan Inc., Head of Global Biopharmaceuticals at Sandoz and he held various senior positions at Biogen Inc, Sanofi-Synthelabo, and Numico.
Vink replaces Harry Welten, Chairman of the board since 2015. Biognosys is a specialist for next-generation proteomics solutions for drug discovery. The company was founded in 2008 as a ETH-Spin-off. Dr Oliver Rinner, CEO of Biognosys, explained: “I am delighted to welcome Dr Vink as our Chairman now that we are realizing our next stage of growth following the completion of our latest Financing Round. I would also like to thank our prior Chairman, Harry Welten, for his many years of service to our board, guiding the company from its start-up phase to an established leader in proteomics services and products.”